Understanding Molecular Recognition at the Rhodopsin/Transducin Interface

了解视紫红质/转导蛋白界面的分子识别

• 批准号: 7333769
• 负责人: Christina Marie Taylor
• 金额: $ 4.96万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7333769
• 关键词: Binding; Binding Proteins; C-terminal; Chemistry; Computational Technique; Computer Simulation; Computer software; Computing Methodologies; Data; Disease; Docking; Drug Delivery Systems; G-Protein-Coupled Receptors; GTP-Binding Proteins; Goals; Helix (Snails); Lead; Learning; Libraries; Ligands; Light; Literature; Marketing; Measurement; Membrane; Methodology; Methods; Modeling; Molecular; Molecular Conformation; Mutation; Night Blindness; Numbers; Pathologic Processes; Peptides; Pharmaceutical Preparations; Play; Procedures; Process; Proteins; Protons; Range; Reaction; Research; Retinal; Retinal Diseases; Rhodopsin; Roentgen Rays; Role; Signal Transduction; Signaling Protein; Spin Labels; Structure; Techniques; Testing; Therapeutic; Transducin; Vision; Work; analog; base; combinatorial chemistry; design; disease-causing mutation; drug discovery; ear helix; extracellular; high throughput screening; inhibitor/antagonist; molecular modeling; molecular recognition; mutant; peptidomimetics; protein protein interaction; prototype; small molecule; small molecule libraries

DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCRs) are involved in many pathological processes and implicated in many diseases; over 50% of the drugs target GPCRs. Rhodopsin, the retinal GPCR, is used as the prototypical GPCR because it is the only GPCR for which an X-ray structure exists. Following light exposure, rhodopsin changes conformation (R->R*), allowing its G-protein, transducin, to bind. The interaction of the transducin C-terminal region Gtalpha(340-350) with the intracellular loops of rhodopsin is critical for GDP/GTP exchange and subsequent signal amplification in the vision cascade. Some congenital mutations in rhodopsin cause rhodopsin to stay in the R* state, leading to constitutive signal amplification. The goal of my research is to learn about the molecular recognition between rhodopsin and transducin and develop a molecular therapeutic to block this interaction. Using both experimental and computational techniques, I will determine the binding mode and residue-residue interactions of Gtalpha(340-350) peptides and peptidomimetics with R*. I will use parallel techniques to derive a small molecule to inhibit the rhodopsin/transducin interaction. First, I will use modeling software and computational high-throughput screening to design an inhibitor. Secondly, I will explore the use of high-efficiency reactions to generate peptidomimetic compounds using rhodopsin to template the reaction. Statement of Relevance: Despite a large number of drugs on the market targeting G-protein coupled receptors (GPCRs), very little is known about how GPCRs interact with other proteins and signal downstream processes. Using rhodopsin, the prototypical GPCR involved in vision, I will determine how rhodopsin and transducin (rhodopsin's G-protein) interact using experimental and computational methods, and I will design and test a small molecule to block this interaction. This work will provide general information about how GPCRs interact with G-proteins and potentially lead to a small molecule therapeutic for some congenital retinal diseases.

描述（由申请人提供）：g蛋白偶联受体（gpcr）参与许多病理过程并涉及许多疾病；超过50%的药物靶向gpcr。视紫红质，视网膜GPCR，被用作GPCR的原型，因为它是唯一存在x射线结构的GPCR。在光照下，视紫红质改变构象（R->R*），允许其g蛋白，转导蛋白结合。在视觉级联中，传导蛋白c端区Gtalpha（340-350）与视紫红质胞内环的相互作用对于GDP/GTP交换和随后的信号放大至关重要。一些先天性视紫质突变使视紫质停留在R*状态，导致本构信号放大。我的研究目标是了解视紫红质和转导蛋白之间的分子识别，并开发一种分子治疗方法来阻断这种相互作用。使用实验和计算技术，我将确定Gtalpha（340-350）肽和肽拟物与R*的结合模式和残基-残基相互作用。我将使用平行技术来获得一个小分子来抑制视紫红质/转导蛋白的相互作用。首先，我将使用建模软件和计算高通量筛选来设计抑制剂。其次，我将探索使用高效反应生成拟肽化合物使用视紫红质模板的反应。相关性声明：尽管市场上有大量靶向g蛋白偶联受体（gpcr）的药物，但对gpcr如何与其他蛋白质相互作用以及信号下游过程知之甚少。使用视紫红质，参与视觉的典型GPCR，我将使用实验和计算方法确定视紫红质和转导蛋白（视紫红质的g蛋白）如何相互作用，我将设计和测试一个小分子来阻止这种相互作用。这项工作将提供关于gpcr如何与g蛋白相互作用的一般信息，并可能导致一些先天性视网膜疾病的小分子治疗。